156 related articles for article (PubMed ID: 19858082)
21. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
[TBL] [Abstract][Full Text] [Related]
22. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Schultheis B; Kummer G; Zeth M; Brendel E; Xia C; Kornacker M; Strumberg D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):333-9. PubMed ID: 21735354
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
24. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.
Procopio G; Verzoni E; Bracarda S; Ricci S; Sacco C; Ridolfi L; Porta C; Miceli R; Zilembo N; Bajetta E
Br J Cancer; 2011 Apr; 104(8):1256-61. PubMed ID: 21448165
[TBL] [Abstract][Full Text] [Related]
25. Acute aortic dissection in a patient receiving gemcitabine and cisplatin.
Madden GW; Ishaq MK; Gupta R
Am J Ther; 2014; 21(1):e21-5. PubMed ID: 23344098
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib-induced eruptive melanocytic lesions.
Kong HH; Sibaud V; Chanco Turner ML; Fojo T; Hornyak TJ; Chevreau C
Arch Dermatol; 2008 Jun; 144(6):820-2. PubMed ID: 18559790
[No Abstract] [Full Text] [Related]
27. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
Kim C; Lee JL; Choi YH; Kang BW; Ryu MH; Chang HM; Kim TW; Kang YK
Invest New Drugs; 2012 Feb; 30(1):306-15. PubMed ID: 20839031
[TBL] [Abstract][Full Text] [Related]
28. Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
Flaherty KT
Cancer; 2010 Jan; 116(1):4-7. PubMed ID: 19890962
[No Abstract] [Full Text] [Related]
29. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
Richey SL; Ng C; Lim ZD; Jonasch E; Tannir NM
J Clin Oncol; 2011 Mar; 29(8):e203-5. PubMed ID: 21172884
[No Abstract] [Full Text] [Related]
30. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
Ryan CW; Goldman BH; Lara PN; Mack PC; Beer TM; Tangen CM; Lemmon D; Pan CX; Drabkin HA; Crawford ED;
J Clin Oncol; 2007 Aug; 25(22):3296-301. PubMed ID: 17664477
[TBL] [Abstract][Full Text] [Related]
32. [Sorafenib(Nexavar)].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
[TBL] [Abstract][Full Text] [Related]
33. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
LoConte NK; Holen KD; Schelman WR; Mulkerin DL; Deming DA; Hernan HR; Traynor AM; Goggins T; Groteluschen D; Oettel K; Robinson E; Lubner SJ
Invest New Drugs; 2013 Aug; 31(4):943-8. PubMed ID: 23263993
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
Negrier S; Jäger E; Porta C; McDermott D; Moore M; Bellmunt J; Anderson S; Cihon F; Lewis J; Escudier B; Bukowski R
Med Oncol; 2010 Sep; 27(3):899-906. PubMed ID: 19757215
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
36. Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.
Ide S; Soda H; Hakariya T; Takemoto S; Ishimoto H; Tomari S; Sawai T; Nagashima S; Furukawa M; Nakamura Y; Kohno S
Lung Cancer; 2010 Feb; 67(2):248-50. PubMed ID: 19897274
[TBL] [Abstract][Full Text] [Related]
37. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
38. Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
Edeline J; Laguerre B; Rolland Y; Patard JJ
Ann Oncol; 2010 Jan; 21(1):186-7. PubMed ID: 19875754
[No Abstract] [Full Text] [Related]
39. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Mego M; Reckova M; Obertova J; Sycova-Mila Z; Brozmanova K; Mardiak J
Ann Oncol; 2007 Nov; 18(11):1906-7. PubMed ID: 17993633
[No Abstract] [Full Text] [Related]
40. Molecular therapy of pancreatic cancer.
Plentz RR; Manns MP; Greten TF
Minerva Endocrinol; 2010 Mar; 35(1):27-33. PubMed ID: 20386525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
